OKYO Pharma to Present at International Tear Film and Ocular Surface Society Conference
OKYO Pharma (NASDAQ: OKYO) announces its participation in the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy from October 30 to November 2, 2024. The company will present results from their dry eye disease trial and discuss their ongoing Phase 2 trial of OK-101 for Neuropathic Corneal Pain treatment at Tufts Medical Center.
Chief Scientific Officer Dr. Raj Patil will present 'Efficacy and Safety Results of First-in-Human Phase 2 Trial of OK-101 in Dry Eye Patients' during Poster Session III on November 2, 2024. The company aims to develop treatments for both neuropathic corneal pain, which currently lacks FDA-approved therapy, and inflammatory dry eye disease, representing a multi-billion-dollar market opportunity.
OKYO Pharma (NASDAQ: OKYO) annuncia la sua partecipazione alla 10ª Conferenza Internazionale della Tear Film & Ocular Surface Society a Venezia, Italia, dal 30 ottobre al 2 novembre 2024. L'azienda presenterà i risultati del suo studio sulla malattia dell'occhio secco e discuterà il suo studio di Fase 2 in corso di OK-101 per il trattamento del dolore corneale neuropatico al Tufts Medical Center.
Il Chief Scientific Officer Dr. Raj Patil presenterà 'Risultati di Efficacia e Sicurezza del Primo Studio di Fase 2 su Umana di OK-101 in Pazienti con Occhio Secco' durante la Sessione Poster III il 2 novembre 2024. L'azienda punta a sviluppare trattamenti sia per il dolore corneale neuropatico, che attualmente non ha terapie approvate dalla FDA, sia per la malattia infiammatoria dell'occhio secco, rappresentando un'opportunità di mercato da miliardi di dollari.
OKYO Pharma (NASDAQ: OKYO) anuncia su participación en la 10ª Conferencia Internacional de la Tear Film & Ocular Surface Society en Venecia, Italia, del 30 de octubre al 2 de noviembre de 2024. La compañía presentará los resultados de su ensayo sobre la enfermedad del ojo seco y discutirá su ensayo de Fase 2 en curso de OK-101 para el tratamiento del dolor corneal neuropático en el Tufts Medical Center.
El Director Científico Dr. Raj Patil presentará 'Resultados de Eficacia y Seguridad del Primer Ensayo de Fase 2 en Humanos de OK-101 en Pacientes con Ojo Seco' durante la Sesión de Pósters III el 2 de noviembre de 2024. La empresa tiene como objetivo desarrollar tratamientos tanto para el dolor corneal neuropático, que actualmente carece de terapia aprobada por la FDA, como para la enfermedad inflamatoria del ojo seco, representando una oportunidad de mercado de miles de millones de dólares.
OKYO Pharma (NASDAQ: OKYO)는 2024년 10월 30일부터 11월 2일까지 이탈리아 베니스로 열리는 제10회 국제 Tear Film & Ocular Surface Society Conference에 참가한다고 발표했습니다. 이 회사는 안구건조증 시험의 결과를 발표하고 Tufts Medical Center에서 뉴로패틱 각막 통증 치료를 위한 OK-101의 진행 중인 2상 시험에 대해 논의할 것입니다.
최고 과학 책임자 Raj Patil 박사는 2024년 11월 2일 포스터 세션 III에서 '안구건조증 환자에서 OK-101의 1상 임상시험의 효능 및 안전성 결과'를 발표할 예정입니다. 이 회사는 현재 FDA 승인이 없는 신경병성 각막 통증과 염증성 안구건조증에 대한 치료제를 개발하는 것을 목표로 하며, 이는 수십억 달러 규모의 시장 기회를 나타냅니다.
OKYO Pharma (NASDAQ: OKYO) annonce sa participation à la 10e Conférence internationale de la Tear Film & Ocular Surface Society à Venise, en Italie, du 30 octobre au 2 novembre 2024. L'entreprise présentera les résultats de son essai sur la maladie de l'œil sec et discutera de son essai de Phase 2 en cours de OK-101 pour le traitement de la douleur cornéenne neuropathique au Tufts Medical Center.
Le directeur scientifique Dr. Raj Patil présentera 'Résultats d'efficacité et de sécurité du premier essai clinique chez l'homme de Phase 2 de OK-101 chez des patients atteints de l'œil sec' lors de la session de posters III le 2 novembre 2024. L'entreprise vise à développer des traitements à la fois pour la douleur cornéenne neuropathique, qui ne dispose actuellement d'aucune thérapie approuvée par la FDA, et pour la maladie inflammatoire de l'œil sec, représentant une opportunité de marché de plusieurs milliards de dollars.
OKYO Pharma (NASDAQ: OKYO) gibt seine Teilnahme an der 10. Internationalen Tear Film & Ocular Surface Society Conference in Venedig, Italien, vom 30. Oktober bis 2. November 2024 bekannt. Das Unternehmen wird die Ergebnisse seiner Studie zur Erkrankung des trockenen Auges präsentieren und über seine laufende Phase-2-Studie zu OK-101 zur Behandlung von neuropathischen Hornhautschmerzen am Tufts Medical Center berichten.
Der Chief Scientific Officer Dr. Raj Patil wird am 2. November 2024 während der Poster-Sitzung III 'Wirkungs- und Sicherheitsdaten der ersten Phase-2-Studie an Menschen zu OK-101 bei Patienten mit trockenem Auge' präsentieren. Das Unternehmen hat sich zum Ziel gesetzt, Behandlungen sowohl für neuropathische Hornhautschmerzen, für die es derzeit keine von der FDA zugelassene Therapie gibt, als auch für die entzündliche Krankheit des trockenen Auges zu entwickeln, was eine Marktchance in Milliardenhöhe darstellt.
- None.
- None.
LONDON and NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory dry eye disease (DED), a multi-billion-dollar market, is pleased to announce that it will be presenting at the 10th International Tear Film & Ocular Surface Society Conference in Venice, Italy during October 30 - November 2, 2024. The OKYO management team will be participating in one-on-one meetings to discuss the dry eye disease trial results, and also the recent opening of our Phase 2 trial of OK-101 to treat patients with Neuropathic Corneal Pain at Tufts Medical Center, Boston, Massachusetts, USA.
Presentation Information:
Event: Tear Film and Ocular Surface Society (TFOS) Conference
Presentation Title: Efficacy and Safety Results of First-in-Human Phase 2 Trial of OK-101 in Dry Eye Patients
Presented By: Raj Patil, Ph.D., Chief Scientific Officer of OKYO Pharma
Date of Presentation: Saturday, November 2, 2024
Session Details: Poster Session III
“We are thrilled to share our clinical findings with the TFOS community,” said Dr. Gary S. Jacob, Ph.D., CEO of OKYO Pharma. “Dry Eye Disease is a multifactorial and often frustrating condition for both patients and eye care providers, and our goal is to provide an effective, long-lasting treatment that improves the quality of life for millions who struggle with DED daily.”
For further information on the ongoing Phase 2 trial of OK-101 to treat Neuropathic Corneal Pain, or to inquire about participation, please visit https://clinicaltrials.gov/study/NCT06637527?intr=OK-101&rank=2
About Dry Eye Disease (DED)
DED is a common condition that occurs when one’s tears are unable to adequately lubricate the eyes. This condition affects approximately 49 million people in the United States alone and has been difficult to positively diagnose and treat due to the multifactorial nature of the condition. Several contributing factors can lead to this condition, including age, sex, certain medical conditions, reduced tear production and tear film dysfunction.
About NCP
Neuropathic corneal pain (NCP) is a condition that causes pain and sensitivity of the eyes, face, or head. The exact cause of NCP is unknown but thought to result from nerve damage to the cornea combined with inflammation. NCP, which can exhibit as a severe, chronic, or debilitating condition in patients suffering from a host of ophthalmic conditions, is presently treated by various topical and systemic treatments in an off-label fashion. There are no approved commercial treatments currently available for this condition.
About OK-101
OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide technology to produce a novel long-acting drug candidate for treating dry eye disease. OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP), respectively, and is designed to combat washout through the inclusion of the lipid anchor built into the drug molecule to enhance the residence time of OK-101 within the ocular environment. OK-101 showed clear statistical significance in multiple endpoints in a recently completed Phase 2, multi-center, double-masked, placebo-controlled trial of OK-101 to treat DED, and is presently being evaluated in a randomized, placebo-controlled, double-masked Phase 2 trial to treat 48 NCP patients.
About OKYO
OKYO Pharma Limited (NASDAQ: OKYO) is a clinical stage biopharmaceutical company developing innovative therapies for the treatment of NCP and DED, with ordinary shares listed for trading on the NASDAQ Capital Market. OKYO is focused on the discovery and development of novel molecules to treat NCP and inflammatory DED. In addition to the recently completed Phase 2 trial of OK-101 to treat DED patients, OKYO is also evaluating OK-101 to treat NCP patients with the just announced opening of a Phase 2 trial to treat the debilitating conditions of NCP. For further information, please visit www.okyopharma.com.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2024. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.
Enquiries:
OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer | 917-497-7560 |
Business Development & Investor Relations | Paul Spencer | +44 (0)20 7495 2379 |
FAQ
What will OKYO Pharma present at the TFOS Conference in Venice 2024?
What conditions is OKYO Pharma developing treatments for in 2024?
Where is OKYO Pharma conducting its Phase 2 trial of OK-101 for Neuropathic Corneal Pain?